MAZE (Maze Therapeutics) Volatility: 93.58% (As of Jun. 25, 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $27.02
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Volatility?

Maze Therapeutics MAZE +1.31% 14 Volatility is 93.58% as of Jun. 25, 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Maze Therapeutics's Volatility is 93.58%.

Maze Therapeutics  (NAS:MAZE) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Maze Therapeutics Volatility Related Terms

MAZE vs FTRE, ARDX, MBX: Volatility Comparison

For the Biotechnology subindustry, Maze Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's Volatility falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics  (NAS:MAZE) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 93.58% mean?
Maze Therapeutics (MAZE) has a Volatility of 93.58% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' Volatility too high?
Maze Therapeutics' current Volatility is 93.58%. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Volatility compare to FTRE and ARDX?
Maze Therapeutics' Volatility of 93.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current Volatility is 93.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Volatility of 93.58%. The current Volatility is 93.58%. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Volatility is 93.58% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.02
Price